Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...
3033 Science Park Road
San Diego, CA 92121
Founded in 2008
Receptos, Inc. Announces Executive Changes
Aug 27 15
Receptos, Inc. entered into an agreement and plan of merger with Celgene Corporation. In accordance with the terms of the Merger Agreement, as of the effective time, each of William H. Rastetter, Ph. D., Kristina Burow, Mary Lynne Hedley, Ph. D., Richard A. Heyman, Ph. D., Erle T. Mast, Mary Szela, S. Edward Torres and Faheem Hasnain ceased serving as directors of the company, and the directors of Purchaser at the Effective Time became the directors of the Surviving Corporation. Additionally, in accordance with the terms of the Merger Agreement, as of the Effective Time, each of Faheem Hasnain, Graham Cooper, Sheila K. Gujrathi, M.D., Marcus F. Boehm, Ph.D. and Robert Peach, Ph.D. ceased serving as officers of the Company.
Receptos, Inc.(NasdaqGS:RCPT) dropped from NASDAQ Composite Index
Aug 27 15
Receptos, Inc. will be removed from Nasdaq Composite Index.
Receptos, Inc.(NasdaqGS:RCPT) dropped from NASDAQ Biotechnology Index
Aug 25 15
Receptos, Inc. will be removed from NASDAQ Biotech Index.